Paclitaxel-hyaluronic acid conjugate - Fidia Farmaceutici

Drug Profile

Paclitaxel-hyaluronic acid conjugate - Fidia Farmaceutici

Alternative Names: HA-paclitaxel bioconjugate; Hyaluronic acid-paclitaxel; Oncofid-P; Oncofid®P-B; Paclitaxel-hyaluronic acid

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fidia Farmaceutici
  • Class Antineoplastics; Drug conjugates; Glycosaminoglycans; Paclitaxels; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 20 Mar 2018 Fidia Farmaceutici completes a phase II trial in Bladder cancer in Spain, Italy, Germany (Intravesicular)
  • 19 Mar 2018 Paclitaxel-hyaluronic acid conjugate is still in phase II trials for Bladder cancer in Germany, Italy and Spain
  • 19 Mar 2018 Interim efficacy and adverse events data from a phase II trial in Bladder cancer presented at 33rd Congress of the European Association of Urology (EAU-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top